Plasma β-amyloid1–42 reference values in cognitively normal subjects
In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values. Plasma sa...
Saved in:
Published in | Journal of the neurological sciences Vol. 391; pp. 120 - 126 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
15.08.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-510X 1878-5883 1878-5883 |
DOI | 10.1016/j.jns.2018.06.006 |
Cover
Loading…
Abstract | In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values.
Plasma samples were obtained from 245 subjects, with a wide age-range (19–89 years), enrolled at the Unit of Laboratory Medicine of the “Azienda Ospedaliera Cardinale G. Panico” (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1–42 was used for the analysis.
The mean (SD) concentration of plasma Aβ1–42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1–42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1–42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77–9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01–31.00).
The present study proposes reference values for plasma Aβ1–42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice.
•Aβ1–42 plasma levels evaluated in cognitively normal subjects.•Plasma samples obtained from 245 subjects, 19–89 years of age.•Three different age groups established: age ≤ 34 years, 35 ≤ age ≤ 64 years, age > 64.•Significant differences among the three age subgroups. |
---|---|
AbstractList | In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values.
Plasma samples were obtained from 245 subjects, with a wide age-range (19–89 years), enrolled at the Unit of Laboratory Medicine of the “Azienda Ospedaliera Cardinale G. Panico” (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1–42 was used for the analysis.
The mean (SD) concentration of plasma Aβ1–42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1–42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1–42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77–9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01–31.00).
The present study proposes reference values for plasma Aβ1–42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice.
•Aβ1–42 plasma levels evaluated in cognitively normal subjects.•Plasma samples obtained from 245 subjects, 19–89 years of age.•Three different age groups established: age ≤ 34 years, 35 ≤ age ≤ 64 years, age > 64.•Significant differences among the three age subgroups. In clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1-42 plasma concentrations in cognitively normal subjects and to propose reference values.BACKGROUNDIn clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1-42 plasma concentrations in cognitively normal subjects and to propose reference values.Plasma samples were obtained from 245 subjects, with a wide age-range (19-89 years), enrolled at the Unit of Laboratory Medicine of the "Azienda Ospedaliera Cardinale G. Panico" (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1-42 was used for the analysis.METHODSPlasma samples were obtained from 245 subjects, with a wide age-range (19-89 years), enrolled at the Unit of Laboratory Medicine of the "Azienda Ospedaliera Cardinale G. Panico" (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1-42 was used for the analysis.The mean (SD) concentration of plasma Aβ1-42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1-42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1-42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77-9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01-31.00).RESULTSThe mean (SD) concentration of plasma Aβ1-42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1-42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1-42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77-9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01-31.00).The present study proposes reference values for plasma Aβ1-42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice.CONCLUSIONThe present study proposes reference values for plasma Aβ1-42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice. |
Author | Tortelli, Rosanna Arcuti, Simona Barone, Roberta Cardinali, Roberta Piccininni, Marco Logroscino, Giancarlo Brescia, Vincenzo Capozzo, Rosa Zecca, Chiara Abbrescia, Daniela Seripa, Davide Barulli, Maria Rosaria Panza, Francesco |
Author_xml | – sequence: 1 givenname: Chiara surname: Zecca fullname: Zecca, Chiara email: neurodeg.uniba@piafondazionepanico.it organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy – sequence: 2 givenname: Rosanna surname: Tortelli fullname: Tortelli, Rosanna organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 3 givenname: Francesco surname: Panza fullname: Panza, Francesco organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 4 givenname: Simona surname: Arcuti fullname: Arcuti, Simona organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 5 givenname: Marco surname: Piccininni fullname: Piccininni, Marco organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 6 givenname: Rosa surname: Capozzo fullname: Capozzo, Rosa organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 7 givenname: Maria Rosaria surname: Barulli fullname: Barulli, Maria Rosaria organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 8 givenname: Roberta surname: Barone fullname: Barone, Roberta organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy – sequence: 9 givenname: Roberta surname: Cardinali fullname: Cardinali, Roberta organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy – sequence: 10 givenname: Daniela surname: Abbrescia fullname: Abbrescia, Daniela organization: Laboratory of Epidemiology and Biostatistics, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Castellana, Bari, Italy – sequence: 11 givenname: Davide surname: Seripa fullname: Seripa, Davide organization: Geriatric Unit & Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Foggia, Italy – sequence: 12 givenname: Vincenzo surname: Brescia fullname: Brescia, Vincenzo organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy – sequence: 13 givenname: Giancarlo surname: Logroscino fullname: Logroscino, Giancarlo email: giancarlo.logroscino@uniba.it organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy |
BookMark | eNqFkL1OwzAUhS1UJNrCA7BlZEnwXxxbTKiCglQJBpDYLMe5QQ6uA3FbqRvvwJvwIDwET4KrMrEw3eU7R-d-EzQKfQCETgkuCCbivCu6EAuKiSywKDAWB2hMZCXzUko2QmOMKc1Lgp-O0CTGDidCSjVG83tv4tJkX5-5WW597xry_f7BaTZACwMEC9nG-DXEzIXM9s_BrdwG_DYL_bA0PovrugO7isfosDU-wsnvnaLH66uH2U2-uJvfzi4XORBWVjmvakFJrawUHDhRjPFK8bphSjailo3lbV0J0zJhBW1ZaaFqeK3aFttSMLBsis72va9D_5ZmrfTSRQvemwD9OmqKpaRKYFIl9GKPQtqzcTDoaN3uo8YNabJueqcJ1jt9utNJn97p01joJCel1Z-09S44a_wLbP_J_gCryXtE |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
DBID | 7X8 |
DOI | 10.1016/j.jns.2018.06.006 |
DatabaseName | MEDLINE - Academic |
DatabaseTitle | MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1878-5883 |
EndPage | 126 |
ExternalDocumentID | S0022510X18302569 |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABGSF ABIVO ABJNI ABLJU ABMAC ABMZM ABTEW ABUDA ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACVFH ADBBV ADCNI ADEZE ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM L7B LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSN SSU SSZ T5K Z5R ~G- AACTN AADPK AAIAV ABLVK ABYKQ AFCTW AFKWA AJOXV AMFUW DOVZS EFLBG LCYCR RIG ZA5 7X8 AGRNS |
ID | FETCH-LOGICAL-e1357-47b621b9c864e419334794bd398d6b8dc4fb76af36c62f35ce7d4b9ff0c563ec3 |
IEDL.DBID | .~1 |
ISSN | 0022-510X 1878-5883 |
IngestDate | Thu Jul 10 18:03:18 EDT 2025 Fri Feb 23 02:33:31 EST 2024 Tue Aug 26 16:31:56 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | APP Plasma Biomarker Aβ1–40 ALT DSM-IV-TR DP Reference values CDR Aβ SD ANOVA CSF Hb IC Aβ1–42 SP RIs Alzheimer's disease IFCC BMI β-amyloid CLSI AST AD Aβ peptide ESR HOMA Index TSH NINCDS-ADRDA EDTA MCI CV UPDRS-III GGT SPs PET ELISA |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-e1357-47b621b9c864e419334794bd398d6b8dc4fb76af36c62f35ce7d4b9ff0c563ec3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PQID | 2088296017 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2088296017 elsevier_sciencedirect_doi_10_1016_j_jns_2018_06_006 elsevier_clinicalkey_doi_10_1016_j_jns_2018_06_006 |
PublicationCentury | 2000 |
PublicationDate | 2018-08-15 20180815 |
PublicationDateYYYYMMDD | 2018-08-15 |
PublicationDate_xml | – month: 08 year: 2018 text: 2018-08-15 day: 15 |
PublicationDecade | 2010 |
PublicationTitle | Journal of the neurological sciences |
PublicationYear | 2018 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Figurski, Waligorska, Toledo (bb0140) 2012; 8 Van Oijen, Hofman, Soares (bb0145) 2006; 5 Dubois, Feldman, Jacova (bb0050) 2014; 13 Petersen, Smith, Waring (bb0250) 1999; 56 Shaw, Vanderstichele, Knapik-Czajka (bb0080) 2011; 121 American Psychiatric Association (bb0255) 2000 Kim, Kim, Cho (bb0295) 2016; 36 Yaffe, Weston, Graff-Radford (bb0160) 2011; 305 Hertze, Minthon, Zetterberg (bb0075) 2010; 21 Newell, Hyman, Growdon, Hedley-Whyte (bb0005) 1999; 58 Solberg, Petit, International Federation of Clinical Chemistry (IFCC) (bb0190) 1988; 26 Schupf, Tang, Fukuyama (bb0270) 2008; 105 Hansson, Stomrud, Vanmechelen (bb0165) 2012; 28 Folstein, Folstein, Mchugh (bb0240) 1975; 12 Mormino (bb0320) 2014; 24 Sperling, Aisenb, Beckettc (bb0040) 2011; 7 Mckhann, Drachman, Folstein (bb0260) 1984; 34 CLSI and IFCC, C28-A3 document (bb0210) 2008; vol. 28 Lui, Laws, Li (bb0130) 2010; 20 Ruiz, Pesini, Espinosa (bb0310) 2013; 8 Bateman, Xiong, Benzinger (bb0030) 2012; 367 Solberg, Stamm, International Federation of Clinical Chemistry (IFCC) (bb0195) 1991; 29 Rissman, Trojanowski, Shaw, Aisen (bb0100) 2012; 119 Dybkaer, Solberg, International Federation of Clinical Chemistry (IFCC) (bb0205) 1987; 25 Song, Poljak, Valenzuela (bb0285) 2011; 26 Seubert, Vigo-Pelfrey, Esch (bb0015) 1996; 359 Arai, Lee, Messinger (bb0055) 1991; 30 De Souza, Lamari, Belliard (bb0095) 2011; 82 Fahn, Elton (bb0235) 1987; Vol. 2 Scafato E, Gandin C, Farchi G, I.PR.E.A Working Group et al. Italian project on epidemiology of Alzheimer's disease (I.PR.E.A.): study designand methodology of cross-sectional survey. Aging Clin. Exp. Res. 2005; 17:29–34. Hughes, Berg, Danziger (bb0230) 1982; 140 Mckhann, Knopman, Chertkow (bb0045) 2011; 7 Vanderstichele, Bibl, Engelborghs (bb0305) 2012; 8 Roher, Esh, Kokjohn (bb0125) 2009; 5 Metti, Cauley, Ayonayon (bb0315) 2013; 27 Iwatsubo, Odaka, Suzuki (bb0020) 1993; 13 Pesaresi, Lovati, Bertora (bb0115) 2006; 27 Solberg, International Federation of Clinical Chemistry (IFCC) (bb0180) 1987; 25 Walter, Kaether, Steiner, Haass (bb0010) 2001; 11 Davatzikos, Bhatt, Shaw (bb0085) 2011; 32 Toledo, Vanderstichele, Figurski (bb0135) 2011; 122 Blennow, Mattsson, Schöll (bb0275) 2015; 36 Montenegro, De Michina, Misciagna (bb0215) 2013; 108 Hansson, Zetterberg, Vanmechelen (bb0280) 2010; 31 Fagan, Roe, Xiong (bb0120) 2007; 64 Galasko, Chang, Motter (bb0065) 1998; 55 Chouraki, Beiser, Younkin (bb0170) 2015; 11 Apollonio, Leone, Isella (bb0245) 2005; 26 Koyama, Okereke, Yang (bb0265) 2012; 69 Solberg, International Federation of Clinical Chemistry (IFCC) (bb0200) 1987; 25 Kaffashian, Tzourio, Soumare (bb0175) 2015; 36 Laird, Cai, Savonenko (bb0060) 2005; 25 Shaw, Vanderstichele, Knapik-Czajka (bb0070) 2009; 65 Maggi, Zucchetto, Grigoletto (bb0220) 1994; 6 Boparai, Korc-Grodzicki (bb0300) 2011; 78 Graff-Radford, Crook, Lucas (bb0150) 2007; 64 Villemagne, Burnham, Bourgeat (bb0035) 2013; 12 Seppala, Herukka, Hanninen (bb0155) 2010; 81 Sciacovelli, Sonntag, Padoan (bb0290) 2012; 50 Riemenschneider, Wagenpfeil, Diehl (bb0090) 2002; 58 Buchhave, Minthon, Zetterberg (bb0025) 2012; 69 Mehta, Pirttila, Mehta (bb0110) 2000; 57 Petit Clerc, Solberg, International Federation of Clinical Chemistry (IFCC) (bb0185) 1987; 25 Toledo, Shaw, Trojanowski (bb0105) 2013; 5 |
References_xml | – volume: 24 start-page: 300 year: 2014 end-page: 312 ident: bb0320 article-title: The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations publication-title: Neuropsychol. Rev. – volume: 69 start-page: 98 year: 2012 end-page: 106 ident: bb0025 article-title: Hansson. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia publication-title: Arch. Gen. Psychiatry – volume: 82 start-page: 240 year: 2011 end-page: 246 ident: bb0095 article-title: Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 11 start-page: 249 year: 2015 end-page: 257 ident: bb0170 article-title: Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham heart study publication-title: Alzheimers Dement. – reference: Scafato E, Gandin C, Farchi G, I.PR.E.A Working Group et al. Italian project on epidemiology of Alzheimer's disease (I.PR.E.A.): study designand methodology of cross-sectional survey. Aging Clin. Exp. Res. 2005; 17:29–34. – volume: 122 start-page: 401 year: 2011 end-page: 413 ident: bb0135 article-title: Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI publication-title: Acta Neuropathol. – volume: 7 start-page: 263 year: 2011 end-page: 269 ident: bb0045 article-title: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement. – volume: 58 start-page: 1147 year: 1999 end-page: 1155 ident: bb0005 article-title: Application of the National Institute on Aging (NIA)-Reagan institute criteria for the neuropathological diagnosis of Alzheimer disease publication-title: J. Neuropathol. Exp. Neurol. – volume: 119 start-page: 843 year: 2012 end-page: 850 ident: bb0100 article-title: Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease publication-title: J. Neural Transm. – volume: 29 start-page: 531 year: 1991 end-page: 535 ident: bb0195 article-title: Approved recommendation (1991) on the theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reference values publication-title: J. Clin. Chem. Clin. Biochem. – volume: 8 start-page: 65 year: 2012 end-page: 73 ident: bb0305 article-title: Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative publication-title: Alzheimers Dement. – volume: 55 start-page: 937 year: 1998 end-page: 945 ident: bb0065 article-title: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype publication-title: Arch. Neurol. – volume: 108 start-page: 1108 year: 2013 end-page: 1111 ident: bb0215 article-title: Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy publication-title: Am. J. Gastroenterol. – volume: 36 start-page: 297 year: 2015 end-page: 309 ident: bb0275 article-title: Amyloid biomarkers in Alzheimer's disease publication-title: Trends Pharmacol. Sci. – volume: 31 start-page: 357 year: 2010 end-page: 367 ident: bb0280 article-title: Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment publication-title: Neurobiol. Aging – volume: 11 start-page: 585 year: 2001 end-page: 590 ident: bb0010 article-title: The cell biology of Alzheimer's disease: uncovering the secrets of secretases publication-title: Curr. Opin. Neurobiol. – volume: 359 start-page: 325 year: 1996 end-page: 327 ident: bb0015 article-title: Isolation and quantification of soluble Alzheimer's b-peptide from biological fluids publication-title: Nature – volume: 57 start-page: 100 year: 2000 end-page: 105 ident: bb0110 article-title: Plasma and cerebrospinal fluid levels of β-amyloid proteins 1–40 and 1–42 in Alzheimer disease publication-title: Arch. Neurol. – volume: 25 start-page: 657 year: 1987 end-page: 662 ident: bb0205 article-title: Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values publication-title: J. Clin. Chem. Clin. Biochem. – volume: 56 start-page: 303 year: 1999 end-page: 308 ident: bb0250 article-title: Mild cognitive impairment: clinical characterization and outcome publication-title: Arch. Neurol. – volume: 69 start-page: 824 year: 2012 end-page: 831 ident: bb0265 article-title: Plasma amyloid- β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis publication-title: Arch. Neurol. – volume: 32 year: 2011 ident: bb0085 article-title: Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification publication-title: Neurobiol. Aging – volume: vol. 28 start-page: 1 year: 2008 end-page: 76 ident: bb0210 article-title: Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline – volume: 25 start-page: 645 year: 1987 end-page: 656 ident: bb0200 article-title: Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values publication-title: J. Clin. Chem. Clin. Biochem. – volume: 121 start-page: 597 year: 2011 end-page: 609 ident: bb0080 article-title: Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI publication-title: Acta Neuropathol. – volume: 105 start-page: 14052 year: 2008 end-page: 14057 ident: bb0270 article-title: Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 8 year: 2013 ident: bb0310 article-title: Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates publication-title: PLoS One – volume: 30 start-page: 686 year: 1991 end-page: 693 ident: bb0055 article-title: Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer's disease and control subjects publication-title: Ann. Neurol. – volume: 367 start-page: 795 year: 2012 end-page: 804 ident: bb0030 article-title: Dominantly inherited Alzheimer network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease publication-title: N. Engl. J. Med. – volume: 20 start-page: 1233 year: 2010 end-page: 1242 ident: bb0130 article-title: AIBL research group. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging publication-title: J. Alzheimers Dis. – volume: 25 start-page: 639 year: 1987 end-page: 644 ident: bb0185 article-title: Approved recommendation (1987) on the theory of reference values. Part 2. Selection of individual for the production of reference value publication-title: J. Clin. Chem. Clin. Biochem. – volume: 5 start-page: 18 year: 2009 end-page: 29 ident: bb0125 article-title: Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease publication-title: Alzheimers Dement. – volume: 26 start-page: 365 year: 2011 end-page: 375 ident: bb0285 article-title: Meta-analysis of plasma amyloid-β levels in Alzheimer's disease publication-title: J. Alzheimers Dis. – volume: 28 start-page: 231 year: 2012 end-page: 238 ident: bb0165 article-title: Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: a population-based study publication-title: J. Alzheimers Dis. – volume: 25 start-page: 337 year: 1987 end-page: 342 ident: bb0180 article-title: Approved recommendation (1986) on the theory of reference values. Part 1.The concepts of reference values publication-title: J. Clin. Chem. Clin. Biochem. – volume: 6 start-page: 464 year: 1994 end-page: 473 ident: bb0220 article-title: The Italian longitudinal study on aging (ILSA): design and methods publication-title: Aging (Milano) – volume: 21 start-page: 1119 year: 2010 end-page: 1128 ident: bb0075 article-title: Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years publication-title: J. Alzheimers Dis. – volume: Vol. 2 start-page: 293 year: 1987 end-page: 304 ident: bb0235 article-title: The unified Parkinson's disease rating scale publication-title: Recent Developments in Parkinson's Disease – volume: 34 start-page: 939 year: 1984 end-page: 944 ident: bb0260 article-title: Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease publication-title: Neurology – volume: 305 start-page: 261 year: 2011 end-page: 266 ident: bb0160 article-title: Association of plasma b-amyloid level and cognitive reserve with subsequent cognitive decline publication-title: JAMA – volume: 25 start-page: 11693 year: 2005 end-page: 11709 ident: bb0060 article-title: BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions publication-title: J. Neurosci. – volume: 64 start-page: 343 year: 2007 end-page: 349 ident: bb0120 article-title: Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults publication-title: Arch. Neurol. – volume: 13 start-page: 614 year: 2014 end-page: 629 ident: bb0050 article-title: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria publication-title: Lancet Neurol. – volume: 65 start-page: 403 year: 2009 end-page: 413 ident: bb0070 article-title: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects publication-title: Ann. Neurol. – year: 2000 ident: bb0255 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 26 start-page: 593 year: 1988 end-page: 598 ident: bb0190 article-title: Approved recommendation on the theory of reference values. Part 3. Preparation of individuals and collection of the specimens for the production of reference values publication-title: J. Clin. Chem. Clin. Biochem. – volume: 7 start-page: 280 year: 2011 end-page: 292 ident: bb0040 article-title: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement. – volume: 27 start-page: 244 year: 2013 end-page: 249 ident: bb0315 article-title: Health, aging and body composition study. The demographic and medical correlates of plasma aβ40 and aβ42 publication-title: Alzheimer Dis. Assoc. Disord. – volume: 12 start-page: 357 year: 2013 end-page: 367 ident: bb0035 article-title: Australian imaging biomarkers and lifestyle (AIBL) research group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study publication-title: Lancet Neurol. – volume: 78 start-page: 613 year: 2011 end-page: 626 ident: bb0300 article-title: Prescribing for older adults publication-title: Mt Sinai J. Med. – volume: 50 start-page: 463 year: 2012 end-page: 469 ident: bb0290 article-title: Monitoring quality indicators in laboratory medicine does not automatically result in quality improvement publication-title: Clin. Chem. Lab. Med. – volume: 58 start-page: 1622 year: 2002 end-page: 1628 ident: bb0090 article-title: Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration publication-title: Neurology – volume: 27 start-page: 904 year: 2006 end-page: 905 ident: bb0115 article-title: Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment publication-title: Neurobiol. Aging – volume: 5 start-page: 655 year: 2006 end-page: 660 ident: bb0145 article-title: Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case-cohort study publication-title: Lancet Neurol. – volume: 64 start-page: 354 year: 2007 end-page: 362 ident: bb0150 article-title: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease publication-title: Arch. Neurol. – volume: 36 start-page: 2663 year: 2015 end-page: 2670 ident: bb0175 article-title: Association of plasma beta-amyloid with MRI markers of structural brain aging the 3-City Dijon study publication-title: Neurobiol. Aging – volume: 81 start-page: 1123 year: 2010 end-page: 1127 ident: bb0155 article-title: Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 5 start-page: 8 year: 2013 ident: bb0105 article-title: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker publication-title: Alzheimers Res. Ther. – volume: 8 start-page: 250 year: 2012 end-page: 260 ident: bb0140 article-title: Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's disease neuroimaging initiative study patients publication-title: Alzheimers Dement. – volume: 140 start-page: 566 year: 1982 end-page: 572 ident: bb0230 article-title: A new clinical scale for the staging of dementia publication-title: Br. J. Psychiatry – volume: 12 start-page: 189 year: 1975 end-page: 198 ident: bb0240 article-title: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician publication-title: J. Psychiatr. Res. – volume: 26 start-page: 108 year: 2005 end-page: 116 ident: bb0245 article-title: The frontal assessment battery (FAB): normative values in an Italian population sample publication-title: Neurol. Sci. – volume: 13 start-page: 45 year: 1993 end-page: 53 ident: bb0020 article-title: Visualization of Ab42(43) and Ab40 in senile plaques with specific ab monoclonals: evidence that the initially deposited species is Ab42(43) publication-title: Neuron – volume: 36 start-page: 595 year: 2016 end-page: 598 ident: bb0295 article-title: Reference intervals for plasma amyloid β in Korean adults without cognitive impairment publication-title: Ann. Lab. Med. |
SSID | ssj0006889 |
Score | 2.2336237 |
Snippet | In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The... In clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The... |
SourceID | proquest elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 120 |
SubjectTerms | Alzheimer's disease Aβ peptide Biomarker Plasma Reference values β-amyloid |
Title | Plasma β-amyloid1–42 reference values in cognitively normal subjects |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0022510X18302569 https://dx.doi.org/10.1016/j.jns.2018.06.006 https://www.proquest.com/docview/2088296017 |
Volume | 391 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSsNAEF5KBfEi_uJvWcHr2m72N8dSrFVp8WCht7CbbKClTcW2By_iO_gmPogP4ZO4kyb15yJ4TLIbwmSY-WbnmxmEzh0NhXGhJFYKTrgwDWICJknAnVZOaqvy6Q3dnuz0-c1ADCqoVdbCAK2ysP1Lm55b6-JOvZBm_WE4hBpfr4u0MaDQwkpIKOKD7nVepy-ev2geUuuw7BgOq8vMZs7xGmXQsZsuW3jC0KNvDumXac79TXsLbRZAETeX37KNKi7bQevdIhW-i67uPO6dGPz-RszER93DhH68vPIArwaHYGjk7WZ4mOEVSWj8hDNAqWM8W1g4gpntoX778r7VIcVUBOIoE4pwZWVAbRhryR33-AtqQblNWKgTaXUS89QqaVImYxmkTMROJdyGadqIhWQuZvuomk0zd4Bw7J9xlqM05v2S0mnMPKIxNEnSUAT8EAWlPKKyUNOblshb26hkh40iL8QIhBjlDDl5iPhq048_-de2s1LgkddwSFuYzE0XsMhHAT7Qourof68-RhtwBSfBVJyg6vxx4U49lJjbWq4rNbTWvL7t9D4Bj0HI5g |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB2VVgIuiFWU1Uhco9bxkuRYVZSULuLQSr1FduJIqdoU0fbAjX_gT_gQPoIvwU6TCLggcY0zUTQevXljzwJwq7DHhPK4JTmjFmWiaQmbcMumynUUd6WTTW8YDLk_pg8TNqlAu6iFMWmVOfZvMD1D6_xJI9dm4ylJTI2vtkXcnGDTwopxbwtqpjsVrUKt1e35wxKQuet6RdNwI1BcbmZpXtPUNO3Gmy6eZu7RN5_0C50zl9PZh72cK6LW5ncOoKLSQ9ge5LfhR3D_qKnvXKCPd0vMdeCdRPjz9Y3aqJwdgkwvb7VESYrKPKHZC0oNUZ2h5VqaU5jlMYw7d6O2b-WDESyFCXMs6khuY-mFLqeKagpmykGpjIjnRly6UUhj6XAREx5yOyYsVE5EpRfHzZBxokJyAtV0kapTQKFeoyQjakS7JseNQ6JJjcBRFHvMpnWwC30ERa2mRpdAA25QJIhNA63EwCgxyJLkeB1oKfRjM_8SuykUHmgjNzcXIlWLtXlJBwI61sLO2f8-fQ07_mjQD_rdYe8cds2KORjG7AKqq-e1utTMYiWvcsv5AoM8y5c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+%CE%B2-amyloid1-42+reference+values+in+cognitively+normal+subjects&rft.jtitle=Journal+of+the+neurological+sciences&rft.au=Zecca%2C+Chiara&rft.au=Tortelli%2C+Rosanna&rft.au=Panza%2C+Francesco&rft.au=Arcuti%2C+Simona&rft.date=2018-08-15&rft.issn=1878-5883&rft.eissn=1878-5883&rft.volume=391&rft.spage=120&rft_id=info:doi/10.1016%2Fj.jns.2018.06.006&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-510X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-510X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-510X&client=summon |